About
Natalie Roy D’Amore joined Fast Track Initiative in 2024 as a Venture Partner. She previously spent 13 years at Takeda Pharmaceutical, where she led oncology partnerships and built an early-stage portfolio through strategic alliances with biopharma and academic institutions, and worked as a project leader at Millennium Pharmaceuticals. More recently she served as head of external innovation at Seres Therapeutics, building partnerships for microbiome drug development. She earned her PhD from the University of Ottawa and completed postdoctoral research in John Reed's lab at the Sanford-Burnham Institute.
Invests in
Biotech
Colleagues at Fast Track Initiative
Frequently asked questions
- Who is Natalie Roy D’Amore?
- Natalie Roy D’Amore joined Fast Track Initiative in 2024 as a Venture Partner. She previously spent 13 years at Takeda Pharmaceutical, where she led oncology partnerships and built an early-stage portfolio through strategic alliances with biopharma and academic institutions, and worked as a project leader at Millennium Pharmaceuticals. More recently she served as head of external innovation at Seres Therapeutics, building partnerships for microbiome drug development. She earned her PhD from the University of Ottawa and completed postdoctoral research in John Reed's lab at the Sanford-Burnham Institute.
- Where does Natalie Roy D’Amore work?
- Natalie Roy D’Amore is Venture Partner at Fast Track Initiative.
- What does Natalie Roy D’Amore invest in?
- Natalie Roy D’Amore invests in Biotech.